PMID- 20426905
OWN - NLM
STAT- MEDLINE
DCOM- 20120105
LR  - 20191111
IS  - 1000-467X (Print)
IS  - 1944-446X (Linking)
VI  - 29
IP  - 5
DP  - 2010 May
TI  - Survival analysis of 220 patients with completely resected stage-II non-small 
      cell lung cancer.
PG  - 538-44
AB  - BACKGROUND AND OBJECTIVE: Surgery is the main therapy for patients with stage II 
      non small cell lung cancer (NSCLC), but patients still have an unsatisfactory 
      prognosis even though complete resection is usually possible. Adjuvant 
      chemotherapy provides low rates of clinical benefit as well. We retrospectively 
      analyzed prognostic factors of patients with completely resected stage II NSCLC 
      to find patients with unfavorable factors for proper management. METHODS: 
      Clinical data of 220 patients with complete resections of stage II NSCLC at the 
      Sun Yat sen University Cancer Center between January 1998 and December 2004 were 
      retrospectively analyzed. Cumulative survival was analyzed by the Kaplan Meier 
      method and compared by log rank test. Prognosis was analyzed by the Cox 
      proportional hazards model. RESULTS: The overall 3 and 5 year survival rates were 
      58.8% and 47.9%, respectively. The 3 and 5 year disease free survival rates were 
      45.8% and 37.0%, respectively. Of the 220 patients, 86 (39.1%) had recurrence or 
      metastasis. A univariate analysis demonstrated that age (> 55 years), blood type, 
      the presence of symptoms, chest pain, tumor volume (> 20 cm3), total number of 
      removed lymph nodes (> or = 10), number of involved N1 lymph nodes (> or =3 ), 
      total number of removed N2 lymph nodes (> 6), and the ratio of involved N1 lymph 
      nodes (> or = 35%) were significant prognostic factors for 5 year survival. In 
      the multivariate analysis, age (> 55 years), chest pain, tumor volume (> 20 cm3), 
      total number of removed lymph nodes (> or = 10), and number of involved N1 lymph 
      nodes (> or = 3) were independent prognostic factors for 5 year survival. 
      CONCLUSIONS: For patients with completely resectable stage II NSCLC, having > 55 
      years, presenting chest pain, tumor volumes > 20 cm3, and > or = 3 involved N1 
      lymph nodes were adverse prognostic factors, and > or = 10 removed lymph nodes 
      was a favorable one. Patients with poor prognoses might be treated by individual 
      adjuvant therapy for better survival.
FAU - Dai, Yun
AU  - Dai Y
AD  - State Key Laboratory of Oncology in South China, Guangzhou, Guangdong 510060, PR 
      China. sjzl@gzsums.edu.cn
FAU - Su, Xiao-Dong
AU  - Su XD
FAU - Long, Hao
AU  - Long H
FAU - Lin, Peng
AU  - Lin P
FAU - Fu, Jian-Hua
AU  - Fu JH
FAU - Zhang, Lan-Jun
AU  - Zhang LJ
FAU - Wang, Xin
AU  - Wang X
FAU - Wen, Zhe-Sheng
AU  - Wen ZS
FAU - Zhu, Zhi-Hua
AU  - Zhu ZH
FAU - Zhang, Xu
AU  - Zhang X
FAU - Rong, Tie-Hua
AU  - Rong TH
LA  - eng
PT  - Journal Article
PL  - England
TA  - Chin J Cancer
JT  - Chinese journal of cancer
JID - 101498232
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Non-Small-Cell Lung/complications/drug 
      therapy/*pathology/radiotherapy/*surgery
MH  - Chemotherapy, Adjuvant
MH  - Chest Pain/etiology
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Lung Neoplasms/complications/drug therapy/*pathology/radiotherapy/*surgery
MH  - Lymph Node Excision
MH  - Lymph Nodes/pathology/surgery
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - *Pneumonectomy/methods
MH  - Proportional Hazards Models
MH  - Radiotherapy, Adjuvant
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Tumor Burden
EDAT- 2010/04/30 06:00
MHDA- 2012/01/06 06:00
CRDT- 2010/04/30 06:00
PHST- 2010/04/30 06:00 [entrez]
PHST- 2010/04/30 06:00 [pubmed]
PHST- 2012/01/06 06:00 [medline]
AID - 1944-446X201005538 [pii]
AID - 10.5732/cjc.009.10455 [doi]
PST - ppublish
SO  - Chin J Cancer. 2010 May;29(5):538-44. doi: 10.5732/cjc.009.10455.